Skip to main content

Newsroom press releases

15/03/24 - 13:35

The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)
Financial Data

13/03/24 - 10:23

Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)
Products Molecular

25/01/24 - 7:48

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)
Products Immunodiagnostic

15/12/23 - 17:38

Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)
Financial Data

06/11/23 - 15:44

Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market (506.97 KB)
Products Immunodiagnostic

03/11/23 - 15:51

Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)
Financial Data

24/10/23 - 15:03

Diasorin unveils its new Corporate identity and launches the new Group website: www.diasorin.com (574.08 KB)
Other

27/07/23 - 14:27

Update 2023 Annual Calendar of Corporate Events (104.1 KB)
Other

27/07/23 - 13:18

Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)
Financial Data

17/07/23 - 7:03

DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease (510.4 KB)
Products Immunodiagnostic

03/07/23 - 11:48

Suspension of the effectiveness of the disqualifying accessory administrative sanction imposed by CONSOB to the Chief Executive Officer Mr. Carlo Rosa (102.52 KB)
Other

13/06/23 - 15:18

DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark (578.05 KB)
Products Immunodiagnostic

07/06/23 - 14:40

Communication of total amount of voting rights (7 June 2023) (141.14 KB)
Financial Disclosures

05/06/23 - 21:58

Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment. (107.91 KB)
Other

26/05/23 - 7:10

DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM (159.38 KB)
Acquisition / Partnership

09/05/23 - 11:56

Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)
Financial Data

28/04/23 - 12:52

Shareholders' Meeting 2023 (373.48 KB)
Other

27/03/23 - 15:52

Update 2023 Annual Calendar of Corporate Events (483.89 KB)
Financial Disclosures

27/03/23 - 14:38

Dividend coupon date correction (493.46 KB)
Financial Data

27/03/23 - 13:35

REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)
Financial Data

17/03/23 - 22:05

DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance (155.02 KB)
Products Molecular

28/02/23 - 16:06

Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed (130.89 KB)
Acquisition / Partnership

13/02/23 - 22:03

CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN (165.22 KB)
Acquisition / Partnership

07/02/23 - 12:01

Update 2023 Annual Calendar of Corporate Events (288.3 KB)
Financial Disclosures

01/12/22 - 18:30

2023 Annual Calendar of Corporate Events (288 KB)
Other

09/11/22 - 7:04

DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
Products Molecular

07/11/22 - 7:12

DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
Products Molecular

27/10/22 - 13:44

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
Financial Data

05/10/22 - 6:37

DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
Products Molecular

14/09/22 - 0:29

DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
Products Molecular

03/08/22 - 12:26

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
Financial Data

14/07/22 - 20:00

DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
Products Immunodiagnostic

07/06/22 - 18:06

Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
Other

20/05/22 - 7:08

DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
Products Molecular

09/05/22 - 7:02

DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
Acquisition / Partnership

06/05/22 - 17:33

Update 2022 Annual Calendar of Corporate Events (285.68 KB)
Financial Disclosures

06/05/22 - 16:45

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
Financial Data

02/05/22 - 12:55

Publication of the summary report of the votes cast (280.95 KB)
Financial Disclosures

29/04/22 - 16:26

Shareholders' meeting 2022 (166.12 KB)
Other

22/04/22 - 12:37

New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
Financial Disclosures

13/04/22 - 16:43

DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
Financial Disclosures

08/04/22 - 19:13

Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
Financial Disclosures

08/04/22 - 9:53

Update annual calendar of corporate events 2022 (288.09 KB)
Financial Disclosures

05/04/22 - 9:51

Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
Other

04/04/22 - 18:12

Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
Other

16/03/22 - 17:39

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
Financial Data

08/03/22 - 7:13

DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
Products Molecular

13/01/22 - 7:24

DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
Products Molecular

21/12/21 - 11:07

2022 Annual Calendar of Corporate Events (296.13 KB)
Other

16/12/21 - 22:47

DiaSorin 2022-2025 Strategic Plan (552.15 KB)
Financial Data

30/11/21 - 19:10

DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant (307.83 KB)
Products Molecular

29/11/21 - 7:06

DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer (437.79 KB)
Products Immunodiagnostic

23/11/21 - 7:10

DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark (412.77 KB)
Products Immunodiagnostic

11/11/21 - 16:56

DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021 (862.48 KB)
Financial Data

05/11/21 - 11:22

Weekly report treasury shares buy-back (2.15 MB)
Other

02/11/21 - 20:00

Conclusion treasury shares buy-back plan (294.67 KB)
Other

02/11/21 - 19:57

Weekly report treasury shares buy-back (3.5 MB)
Other

27/10/21 - 16:35

Issuance of the "Physical Settlement Notice" (517.5 KB)
Other

07/10/21 - 11:45

Publication of the summary report of the votes (290.08 KB)
Other

04/10/21 - 12:27

The Extraordinary Shareholders' Meeting of DiaSorin authorizes the convertibility of the equity-linked bond and the share capital increase (297.73 KB)
Other

18/09/21 - 8:16

DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test (407.21 KB)
Products Molecular

30/07/21 - 18:43

Start up of the treasury shares buy-back plan (773.96 KB)
Other

30/07/21 - 12:57

DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex (774.36 KB)
Financial Data

22/07/21 - 18:28

Publication of Information Document under the provisions of the art. 71 of the CONSOB Regulation n. 11971/1999 (303.95 KB)
Other

14/07/21 - 15:05

DiaSorin announces completion of the Acquisition of Luminex Corporation (566.52 KB)
Acquisition / Partnership

09/07/21 - 7:34

DiaSorin obtains all approvals necessary to complete the acquisition of Luminex (560.68 KB)
Acquisition / Partnership

21/06/21 - 18:49

The Shareholders’ meeting of Luminex Corporation approved the merger of Luminex with a U.S. wholly-owned subsidiary of DiaSorin (395.62 KB)
Acquisition / Partnership

15/06/21 - 6:56

DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E (307.58 KB)
Products Immunodiagnostic

07/06/21 - 15:16

Communication on total amount of voting rights (563.42 KB)
Other

03/06/21 - 7:47

DiaSorin signs agreements with Unifarma and Alliance Healthcare for the distribution in Italian pharmacies of the LIAISON® IQ (523.42 KB)
Acquisition / Partnership

25/05/21 - 7:03

DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection (402.64 KB)
Products Immunodiagnostic

21/05/21 - 7:02

DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2 (393.69 KB)
Products Molecular

20/05/21 - 8:27

DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market (506.2 KB)
Products Immunodiagnostic

14/05/21 - 16:10

DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021 (756.07 KB)
Financial Data

28/04/21 - 17:46

DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028 (529.64 KB)
Financial Data

28/04/21 - 7:54

DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028 (563.02 KB)
Financial Data

22/04/21 - 15:58

Shareholders' meeting April 22, 2021 (422.91 KB)
Other

21/04/21 - 7:02

DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology (621.42 KB)
Products Immunodiagnostic

20/04/21 - 18:58

DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark (403.5 KB)
Products Immunodiagnostic

14/04/21 - 10:05

Communication voting rights amount (544.6 KB)
Other

12/04/21 - 11:08

Weekly report treasury shares buy-back (914.42 KB)
Other

11/04/21 - 19:47

DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion (569.09 KB)
Acquisition / Partnership

06/04/21 - 8:53

Start up buy-back plan (774.02 KB)
Other

06/04/21 - 7:06

DiaSorin announces its strategic collaboration with Lumos Diagnostics (438.14 KB)
Acquisition / Partnership

30/03/21 - 7:01

DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test (661.47 KB)
Products Immunodiagnostic

29/03/21 - 7:02

DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S. (494.1 KB)
Products Immunodiagnostic

11/03/21 - 16:37

Dividend coupon date correction (414.99 KB)
Financial Data

11/03/21 - 15:31

Revenues, Profitability and Cash Flow Generation hit record highs in 2020 (748.06 KB)
Financial Data

23/02/21 - 6:11

DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market (413.92 KB)
Products Immunodiagnostic

27/01/21 - 18:50

2021 Annual Calendar of Corporate Events (209.87 KB)
Other

11/01/21 - 18:43

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test (418.29 KB)
Products Immunodiagnostic

29/12/20 - 18:22

DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance (400.67 KB)
Products Molecular

17/12/20 - 17:57

DiaSorin - Policlinico San Matteo Hospital in Pavia vs. Technogenetics (298.96 KB)
Other

07/12/20 - 10:35

Communication on total amount of voting rights (563.18 KB)
Other

04/12/20 - 16:14

Form 3F (November 2020) (10.2 KB)
Other

01/12/20 - 6:33

DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market (566.6 KB)
Products Immunodiagnostic

11/11/20 - 12:41

North America growth drives up revenues and profitability in the first 9 months of 2020 (805.25 KB)
Financial Data

26/10/20 - 18:30

DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients (414.59 KB)
Products Immunodiagnostic

23/10/20 - 19:41

Conclusion treasury shares buy-back plan (314.28 KB)
Other

23/10/20 - 19:37

Weekly report treasury shares buy-back (436.92 KB)
Other

16/10/20 - 18:28

Weekly report treasury shares buy-back (425.19 KB)
Other

01/10/20 - 7:45

DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market (395.31 KB)
Products Immunodiagnostic

01/10/20 - 7:32

DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market (488.09 KB)
Products Immunodiagnostic

23/09/20 - 7:16

DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China (495.78 KB)
Acquisition / Partnership

16/09/20 - 14:30

Update Annual Calendar of Corporate Events 2020 (222.26 KB)
Other

16/09/20 - 7:25

DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens (477.67 KB)
Products Molecular

08/09/20 - 7:31

DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution (506.16 KB)
Acquisition / Partnership

07/09/20 - 18:22

FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay (400.26 KB)
Products Molecular

06/08/20 - 7:25

DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone (391.91 KB)
Products Immunodiagnostic

31/07/20 - 16:04

Weekly report treasury shares buy-back (380.16 KB)
Other

30/07/20 - 13:16

North America business growth drives Group revenues and profitability in H1 2020 (735.54 KB)
Financial Data

24/07/20 - 17:19

Weekly report treasury shares buy-back (363.73 KB)
Other

17/07/20 - 18:19

Weekly report treasury shares buy-back (360.09 KB)
Other

10/07/20 - 18:23

Weekly report treasury shares buy-back (374 KB)
Other

09/07/20 - 7:27

DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study (399.63 KB)
Products Immunodiagnostic

07/07/20 - 7:22

DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay (490.1 KB)
Products Molecular

30/06/20 - 7:25

DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients (397.37 KB)
Products Immunodiagnostic

19/06/20 - 17:20

Weekly report treasury shares buy-back (399.38 KB)
Other

17/06/20 - 16:09

Start up of the treasury shares buy-back plan (481.28 KB)
Other

12/06/20 - 7:30

DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay (478.6 KB)
Products Molecular

10/06/20 - 15:40

Shareholders' Meeting June 10, 2020 (308.25 KB)
Other

03/06/20 - 14:16

The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval for the commercialization in Brazil from ANVISA (397.21 KB)
Products Immunodiagnostic

02/06/20 - 14:58

Communication total amount voting rights (record date) (267.83 KB)

18/05/20 - 11:28

The LIAISON® SARS-COV-2 S1S2 IgG test is the first to receive the approval from Health Canada (308.26 KB)
Products Immunodiagnostic

13/05/20 - 13:15

DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic (741.65 KB)
Financial Data

25/04/20 - 16:49

DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG (403.66 KB)
Products Immunodiagnostic

17/04/20 - 18:25

DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19 (464.49 KB)
Products Immunodiagnostic

07/04/20 - 7:14

IgG test to detect immune response to SARS-CoV-2 (394.92 KB)
Products Immunodiagnostic

26/03/20 - 18:14

Update Annual Calendar of Corporate Events 2020 (277.25 KB)
Other

21/03/20 - 20:29

Shareholders' Meeting date change (288.23 KB)
Other

20/03/20 - 7:28

DiaSorin COVID-19 test has received FDA Emergency Use Authorization (397.04 KB)
Products Molecular

13/03/20 - 17:16

DiaSorin received BARDA funding to develop a rapid COVID-19 test (403.34 KB)
Products Molecular

11/03/20 - 13:43

DiaSorin - Cash flow generation and net profit hit record highs in 2019 (919.6 KB)
Financial Data

10/03/20 - 8:20

DiaSorin - Development of Coronavirus test (404.03 KB)
Products Molecular

02/03/20 - 8:04

DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology (396.06 KB)
Acquisition / Partnership

07/02/20 - 8:06

Communication on total amount of voting rights (281.13 KB)
Other

15/01/20 - 16:51

Annual Calendar of Corporate Events 2020 (124.73 KB)
Other

16/12/19 - 14:10

Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay (571.47 KB)
Products Molecular

06/12/19 - 18:12

Press Release (262.61 KB)
Other

06/12/19 - 18:11

Press Release (262.7 KB)
Other

06/12/19 - 18:08

Communication on total amount of voting rights (281.87 KB)
Other

27/11/19 - 7:59

DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET (531.97 KB)
Products Immunodiagnostic

11/11/19 - 9:46

DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET (159.93 KB)
Products Molecular

06/11/19 - 13:00

Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019 (621.09 KB)
Financial Data

30/10/19 - 9:55

DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET (579.27 KB)
Products Immunodiagnostic

22/10/19 - 14:10

DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET (358.37 KB)
Products Immunodiagnostic

07/10/19 - 10:20

Communication on total amount of voting rights (282.21 KB)
Other

24/09/19 - 10:10

DiaSorin launches VZV Direct molecular test in Europe (369.67 KB)
Products Molecular

31/07/19 - 13:00

DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability. (687.57 KB)
Financial Data

10/06/19 - 18:23

DiaSorin presents its 2019-2022 Industrial Plan (548.2 KB)
Financial Data

05/06/19 - 7:38

DiaSorin and QIAGEN collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease (448.98 KB)
Acquisition / Partnership Immunodiagnostic

29/05/19 - 15:06

DiaSorin launches VZV DIRECT molecular test in the United States (360.87 KB)
Products Molecular

09/05/19 - 13:14

DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019 (728.82 KB)
Financial Data

06/05/19 - 15:19

DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL (416.77 KB)
Products Immunodiagnostic

30/04/19 - 12:28

Update Annual Calendar of Corporate Events 2019 (249.43 KB)
Other

24/04/19 - 17:24

DiaSorin: Shareholders' Meeting 2019 (449.66 KB)
Other

12/04/19 - 8:59

Communication on total amount of voting rights (320.44 KB)
Other

05/04/19 - 9:33

Communication on total amount of voting rights (342.47 KB)
Other

03/04/19 - 20:18

Lists publication (79.68 KB)
Other

03/04/19 - 10:32

DiaSorin launches the anaemia panel on Liaison XL in Europe (416.47 KB)
Products Immunodiagnostic

14/03/19 - 14:16

Growth in revenues, profitability and net profit in 2018 (1.03 MB)
Financial Data

07/03/19 - 11:45

Communication on total amount of voting rights (350.08 KB)
Other

06/03/19 - 8:45

A new Group website for DiaSorin: www.diasoringroup.com (154.5 KB)
Other

07/02/19 - 15:15

Communication on total amount of voting rights (February 7, 2019) (349.86 KB)
Other

31/01/19 - 22:30

DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market (528.02 KB)
Products Immunodiagnostic

03/01/19 - 13:30

DiaSorin launches Simplexa Bordetella Direct Molecular test in the United States (428.56 KB)
Products Molecular

21/12/18 - 11:30

DiaSorin launches 3 new primer pairs for use in molecular testing (438.25 KB)
Products Molecular

04/12/18 - 8:00

DiaSorin's stocks listed in the FTSE MIB (464.63 KB)
Financial Data

19/11/18 - 15:00

DiaSorin launches Simplexa Group B Strep Direct molecular assay in the United States (435.43 KB)
Products Molecular

07/11/18 - 13:00

DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018 (961.72 KB)
Financial Data

17/10/18 - 11:51

DiaSorin launches Simplexa Group B Strep Direct molecular assay in the european market (147.78 KB)
Products Molecular

12/10/18 - 11:47

DiaSorin launches Simplexa VZV Direct molecular assay in the european market (444.81 KB)
Products Molecular

09/10/18 - 11:35

DiaSorin and Meridian enter into a strategic collaboration to sell Helicobacter pylori stool antigen test in the United States and in the United Kingdom (471.21 KB)
Acquisition / Partnership

17/09/18 - 11:28

DiaSorin launches the new LIASON quantiFERON-TB Gold Plus assay as an aid for latent tuberculosis detection in partnership with Qiagen (753.85 KB)
Products Immunodiagnostic

07/08/18 - 8:45

Communication on total amount of voting rights (305.24 KB)
Financial Data

02/08/18 - 12:45

The Board of Directors approves the results for the first half of 2018 (883.1 KB)
Financial Data

27/07/18 - 12:00

DiaSorin launches Hepatitis Delta (HDV) test on LIAISON XL platform (735.03 KB)
Products Immunodiagnostic

03/07/18 - 18:30

Conclusion treasury shares buy-back plan (397.33 KB)
Financial Data

03/07/18 - 18:30

Annex 3F (treasury shares buy back July 2018) (6.59 KB)
Financial Data

03/07/18 - 18:30

Report treasury shares buy-back (287.99 KB)
Financial Data

03/07/18 - 18:30

Annex 3F (treasury shares buy back June 2018) (8.69 KB)
Financial Data

29/06/18 - 18:15

Weekly report treasury shares buy-back (290.62 KB)
Financial Data

22/06/18 - 20:30

Weekly report treasury shares buy-back (290.6 KB)
Financial Data

15/06/18 - 21:00

Weekly report treasury shares buy-back (290.62 KB)
Financial Data

12/06/18 - 14:15

DiaSorin introduces primer pair reagents for use in molecular testing: Anaplasma phagocytophilum, Ehrlichia e Babesia (445.17 KB)
Products Molecular

08/06/18 - 23:15

Weekly report treasury shares buy-back (290.24 KB)
Financial Data

04/06/18 - 13:15

Annex 3F (treasury shares buy back May 2018) (8.54 KB)
Financial Data

01/06/18 - 20:15

Weekly report treasury shares buy-back (290.38 KB)
Financial Data

25/05/18 - 22:30

Weekly report treasury shares buy-back (289.97 KB)
Financial Data

19/05/18 - 1:45

Weekly report treasury shares buy-back (289.76 KB)
Financial Data

11/05/18 - 20:15

Weekly report treasury shares buy-back (290.77 KB)
Financial Data

08/05/18 - 14:30

The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018 (832.84 KB)
Financial Data

03/05/18 - 20:15

Start up treasury shares buy-back plan (354.27 KB)
Financial Data

24/04/18 - 14:00

Annex 3F (treasury shares buy back) (7.77 KB)
Financial Data

23/04/18 - 18:30

Annual General Meeting 2018 (589.65 KB)
Financial Data

19/04/18 - 21:15

Conclusion treasury shares buy-back plan (397.59 KB)
Financial Data

19/04/18 - 21:00

Weekly report treasury shares buy-back (289.29 KB)
Financial Data

13/04/18 - 20:30

Weekly report treasury shares buy-back (290.07 KB)
Financial Data

06/04/18 - 19:45

Weekly report treasury shares buy-back (288.33 KB)
Financial Data

05/04/18 - 12:00

DiaSorin receives FDA clearance for the LIAISON BRAHMS PCT II GEN assay to detect severe bacterial infections (e.g. Sepsis) (737.88 KB)
Products Immunodiagnostic

04/04/18 - 20:00

Start up treasury shares buy-back plan (346.04 KB)
Financial Data

28/03/18 - 18:45

DiaSorin earns FDA clearence extending sample claims for Simplexa HSV 1 & 2 direct molecular test (442.69 KB)
Products Molecular

07/03/18 - 15:30

DiaSorin: FY 2017 Results (1.14 MB)
Financial Data

30/01/18 - 11:45

DiaSorin signs an agreement with the Italian Tax Authority granting tax relief under the Italian Patent Box regime (574.68 KB)
Financial Data

08/01/18 - 9:00

QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems (483.2 KB)
Acquisition / Partnership

08/01/18 - 9:00

QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems (483.2 KB)
Acquisition / Partnership

12/12/17 - 13:15

DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)
Products Molecular

29/11/17 - 19:30

Resignation of a Strategic Executive of the Company (233.58 KB)
Other

09/11/17 - 14:15

GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)
Financial Data

29/09/17 - 15:00

DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)
Financial Data

29/09/17 - 14:15

DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)
Acquisition / Partnership

21/09/17 - 12:45

DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)
Products Molecular

03/08/17 - 14:45

DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)
Financial Data

28/07/17 - 14:45

DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)
Products Molecular

25/07/17 - 21:00

DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)
Acquisition / Partnership

10/07/17 - 13:30

DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)
Products Molecular

26/06/17 - 9:45

DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)
Financial Data

23/06/17 - 9:30

DiaSorin and TECAN to collaborate in new platform development (755.46 KB)
Acquisition / Partnership

22/06/17 - 19:45

DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)
Acquisition / Partnership

23/05/17 - 11:45

DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)
Products Immunodiagnostic

16/05/17 - 13:00

DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)
Products Immunodiagnostic

08/05/17 - 19:30

DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)
Financial Data

27/04/17 - 18:45

DiaSorin - Annual General Meeting 2016 (421.04 KB)
Financial Data

21/04/17 - 18:45

DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)
Products Immunodiagnostic

06/04/17 - 18:00

DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)
Products Immunodiagnostic

08/03/17 - 15:30

The Board of Directors approves the results for FY'16 (1.13 MB)
Financial Data

21/02/17 - 11:30

DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)
Products Molecular

26/01/17 - 12:45

DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)
Products Immunodiagnostic

19/12/16 - 10:00

Co-optation of a Director (333.18 KB)
Financial Data

10/11/16 - 1:00

DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016 (1.05 MB)
Financial Data

02/11/16 - 1:00

DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST (141.53 KB)
Products Molecular

30/08/16 - 2:00

DiaSorin and Beckman Coulter form strategic partnership to bring the LIAISON XL hepatitis and HIV products to the U.S. market (404.63 KB)
Acquisition / Partnership

22/08/16 - 2:00

DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY (158.39 KB)
Products Immunodiagnostic

04/08/16 - 2:00

The Board of Directors approves results for H1'16 (697.16 KB)
Financial Data

28/07/16 - 2:00

DiaSorin starts selling Vitamin D in Japan (724.4 KB)
Products Immunodiagnostic

14/07/16 - 2:00

DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia (278.18 KB)
Products Molecular

10/06/16 - 2:00

Weekly report treasury shares buy-back (289.83 KB)
Financial Data

10/06/16 - 2:00

Conclusion buy-back plan (367.77 KB)
Financial Data

07/06/16 - 2:00

DiaSorin launches the new Helicobacter pylori IgG CLIA test (518.61 KB)
Products Immunodiagnostic

03/06/16 - 2:00

Weekly report treasury shares buy-back (290.21 KB)
Financial Data

30/05/16 - 2:00

Notice filing By-Laws and publication operating procedures for loyalty shares (277.79 KB)
Financial Data

27/05/16 - 2:00

Weekly report treasury shares buy-back (289.34 KB)
Financial Data

20/05/16 - 2:00

Weekly report treasury shares buy-back (290.09 KB)
Financial Data

13/05/16 - 2:00

Acquisition of Focus Diagnostics' Molecular and Immunoassay Product Business (350.22 KB)
Acquisition / Partnership

12/05/16 - 2:00

Start up treasury shares buy-back plan (305.9 KB)
Financial Data

09/05/16 - 2:00

The Board of Directors approves the results for Q1'16 (632.78 KB)
Financial Data

28/04/16 - 2:00

Shareholders' Meeting FY 2015 (365.15 KB)
Financial Data

30/03/16 - 2:00

DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business (133.62 KB)
Acquisition / Partnership

09/03/16 - 1:00

The Board of Directors approves the results for FY'15 (785.08 KB)
Financial Data

11/11/15 - 1:00

The Board of Directors approves the results for Q3'15 (778.06 KB)
Financial Data

09/09/15 - 2:00

DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias (229.24 KB)
Products Molecular

30/07/15 - 2:00

H1'15 Results (777.06 KB)
Financial Data

20/07/15 - 2:00

DiaSorin and Beckman Coulter sign a distribution agreement for China (238.01 KB)
Acquisition / Partnership

28/05/15 - 2:00

DiaSorin launches the test for Campylobacter (241.86 KB)
Products Immunodiagnostic

12/05/15 - 2:00

The Board of Directors approves the results for Q1'15 (553.96 KB)
Financial Data

12/05/15 - 2:00

DiaSorin presents the 2015-2017 industrial plan (305.81 KB)
Other

29/04/15 - 2:00

DiaSorin - launches the test for Brahms-Sepsis (506.96 KB)
Products Immunodiagnostic

23/04/15 - 2:00

DiaSorin supports the Pinocchio Project (251.16 KB)

22/04/15 - 2:00

The Board of Directors approves the 2015-2017 plan that will be presented at the Investor Day (141.85 KB)
Financial Data

22/04/15 - 2:00

Shareholders' meeting approves FY Results 2014 (105.93 KB)
Financial Data

14/04/15 - 2:00

DiaSorin launches the tests for Bordetella pertussis (187.11 KB)
Products Immunodiagnostic

10/04/15 - 2:00

Investor Day-save the date (107.93 KB)
Financial Data

24/03/15 - 1:00

DiaSorin in aid of Haiti's children in partnership with the Francesca Rava Foundation (504.27 KB)

03/03/15 - 1:00

The Board of Directors approves the results for FY'14 (783.03 KB)
Financial Data

24/02/15 - 1:00

DiaSorin supports Emergency in Sudan (612.64 KB)

13/02/15 - 1:00

DiaSorin teams with FISIP for Progetto talenti (612.64 KB)

14/01/15 - 1:00

DiaSorin launches the test for Calprotectin (259.67 KB)
Products Immunodiagnostic

16/12/14 - 1:00

FDA approves 1,25 Vitamin D in the US market (239.73 KB)
Products Immunodiagnostic

09/12/14 - 1:00

DiaSorin launches its first onco-hematology test on LIAISON Iam: the BCR-ABL (265.26 KB)
Products Immunodiagnostic

14/11/14 - 1:00

The Board of Directors approves the results for Q3'14 (785.42 KB)
Financial Data

07/10/14 - 2:00

DiaSorin launches the test for HIV HT on LIAISON (267.4 KB)
Products Immunodiagnostic

18/09/14 - 2:00

DiaSorin launches the stool test for Adenovirus on LIAISON (251.93 KB)
Products Immunodiagnostic

01/08/14 - 2:00

The Board of Directors approves the results for H1'14 (812.25 KB)
Financial Data

22/07/14 - 2:00

DIASORIN CONFIRMS ITS ELIGIBILITY FOR THE PEA-PME (148.49 KB)
Financial Data

30/06/14 - 2:00

DiaSorin launches the test for Herpes Simplex 1 and 2 on LIAISON IAM (250.1 KB)
Products Immunodiagnostic

03/06/14 - 2:00

DiaSorin launches the test for Vitamin D 1,25 on LIAISON (265.57 KB)
Products Immunodiagnostic

09/05/14 - 2:00

The Board of Directors approves the results for Q1'14 (573.05 KB)
Financial Data

23/04/14 - 2:00

Shareholders' meeting approves FY Results 2013 (107.65 KB)
Financial Data

06/03/14 - 1:00

The Board of Directors approves the results for FY'13 (753.73 KB)
Financial Data

18/02/14 - 1:00

DiaSorin launches the new test for PTH on LIAISON (597.92 KB)
Products Immunodiagnostic

11/02/14 - 1:00

DiaSorin launches the test for Rotavirus on stool sample (573.97 KB)
Products Immunodiagnostic

28/01/14 - 1:00

DiaSorin extends its master agreement with Laboratory Corporation of America Holdings till 2018 (336.26 KB)
Acquisition / Partnership

24/01/14 - 1:00

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in China (579.02 KB)
Products Immunodiagnostic

09/01/14 - 1:00

DiaSorin launches the test for Cytomegalovirus on LIAISON IAM (174.61 KB)
Products Immunodiagnostic

08/11/13 - 1:00

The Board of Directors approves the Q3'13 Results (766.57 KB)
Financial Data

29/10/13 - 1:00

DiaSorin signes a 5-year agreement with Roche (432.42 KB)
Acquisition / Partnership

25/10/13 - 2:00

DiaSorin launches the EHEC Toxins test on stool samples (610.05 KB)
Products Immunodiagnostic

10/10/13 - 2:00

DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas) (615.28 KB)
Products Immunodiagnostic

24/09/13 - 2:00

DiaSorin launches the hCG test on its LIAISON XL in the US (599.75 KB)
Products Immunodiagnostic

01/08/13 - 2:00

The Board of Directors approves the results for the H1 '13 (386.67 KB)
Financial Data

24/07/13 - 2:00

DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM (490.89 KB)
Products

11/07/13 - 2:00

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil (113.84 KB)
Products Immunodiagnostic

28/06/13 - 2:00

DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON (78.13 KB)
Products Immunodiagnostic

20/06/13 - 2:00

DiaSorin launches the new test for Parvovirus on LIAISON IAM (488.24 KB)
Products Immunodiagnostic

10/05/13 - 2:00

The Board of Directors approves the results for Q1'13 (763.61 KB)
Financial Data

02/05/13 - 2:00

Compensation Commitee-Errata corrige (179.38 KB)
Financial Data

22/04/13 - 2:00

Shareholders' meeting approves FY Results 2012 (57.22 KB)
Financial Data

17/04/13 - 2:00

FDA approves the Aldosterone assay (439.58 KB)
Products Immunodiagnostic

02/04/13 - 2:00

DiaSorin signs an agreement with Seegene (243.64 KB)
Acquisition / Partnership

08/03/13 - 1:00

The BoD approves FY 2012 results (477.24 KB)
Financial Data

07/03/13 - 1:00

Notification of changes in share capital (46.86 KB)
Financial Data

07/03/13 - 1:00

Notice availability By-Laws (36.87 KB)
Financial Data

07/02/13 - 1:00

Clostridium difficile on LIAISON (available outside the US and Canada only) (79.83 KB)
Products Immunodiagnostic

07/02/13 - 1:00

Notification of changes in share capital (46.89 KB)
Financial Data

07/02/13 - 1:00

Notice availability By-Laws (139.13 KB)
Financial Data

30/01/13 - 1:00

The Board of Directors approves the results for the FY '12 (477.24 KB)
Financial Data

29/01/13 - 1:00

Aldosterone on LIAISON (available outside the US and Canada only) (76.47 KB)
Products Immunodiagnostic

20/12/12 - 1:00

Shareholders' meeting (55.42 KB)
Financial Data

07/11/12 - 1:00

The BoD approves Q3'12 results (280.42 KB)
Financial Data

03/08/12 - 2:00

The BoD approves H1'12 results (279.41 KB)
Financial Data

30/07/12 - 2:00

DiaSorin in India: JV with Trivitron Healthcare (56.16 KB)
Acquisition / Partnership

27/06/12 - 2:00

Notification of changes in share capital (335.97 KB)
Financial Data

11/05/12 - 2:00

The BoD approves Q1'12 results (122.04 KB)
Financial Data

04/05/12 - 2:00

NorDiag acquisition (88.87 KB)
Acquisition / Partnership

23/04/12 - 2:00

2011 statutory financial statement approval (182.29 KB)
Financial Data

10/04/12 - 2:00

Measles and Mumps IgM on LIAISON (available outside the US and Canada only) (43.59 KB)
Products Immunodiagnostic

02/04/12 - 2:00

Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only) (43.85 KB)
Products Immunodiagnostic

30/03/12 - 2:00

Financial calendar update (176.51 KB)
Financial Data

22/03/12 - 1:00

Stock options to employees (175.38 KB)
Financial Data

12/03/12 - 1:00

Agreement with Sonic Healthcare on Vitamin D (179.85 KB)
Acquisition / Partnership

09/03/12 - 1:00

The BoD approves FY 2011 results (357.11 KB)
Financial Data

07/03/12 - 1:00

Notification of changes in share capital (46.84 KB)
Financial Data

17/02/12 - 1:00

DiaSorin became a member of the ISBT (178.96 KB)
Acquisition / Partnership

09/02/12 - 1:00

Notice of change in share capital (46.97 KB)
Financial Data

02/02/12 - 1:00

FDA clearance for 25 OH Vitamin D on LIAISON (180.35 KB)
Products Immunodiagnostic

27/01/12 - 1:00

2012 Financial calendar update (177.74 KB)
Financial Data

25/01/12 - 1:00

Dividend distribution in June (115.61 KB)
Financial Data

19/01/12 - 1:00

Prize for best Italian Company in R&D in the UK (183.95 KB)
Other

13/01/12 - 1:00

2012 Financial calendar (176.51 KB)
Financial Data

12/01/12 - 1:00

New anti HBs II (available outside the US and Canada only) (196.83 KB)
Products Immunodiagnostic

23/12/11 - 1:00

Financial instruments to employees (57.22 KB)
Financial Data

19/12/11 - 1:00

Clostridium Difficile toxins A and B in stool on LIAISON (available outside the US and Canada only) (192.66 KB)
Products Immunodiagnostic

19/11/11 - 1:00

Buy-back plan (35.47 KB)
Financial Data

18/11/11 - 1:00

Financial instruments to employees (56.82 KB)
Financial Data

11/11/11 - 1:00

The BoD approves Q3'11 results (334.35 KB)
Financial Data

28/10/11 - 2:00

Buy-back plan (103.99 KB)
Financial Data

25/10/11 - 2:00

Buy-back plan (104.72 KB)
Financial Data

18/10/11 - 2:00

Buy-back plan (136.18 KB)
Financial Data

17/10/11 - 2:00

2011-2015 Business Plan: a new business wave (195.1 KB)
Financial Data

10/10/11 - 2:00

New Chief Financial Officer (196.26 KB)
Other

06/10/11 - 2:00

Cardinal Health: agreement extended to 2014 (192.57 KB)
Acquisition / Partnership

04/10/11 - 2:00

Buy-back plan (204.92 KB)
Financial Data

01/09/11 - 2:00

Resignation of Chief Financial Officer (177.77 KB)
Other

31/08/11 - 2:00

2011 Financial calendar update (176.4 KB)
Financial Data

03/08/11 - 2:00

The BoD approves H1'11 results (324.48 KB)
Financial Data

11/07/11 - 2:00

Voluntarily removal from the STAR segment (194.93 KB)
Financial Data

13/05/11 - 2:00

The BoD approves Q1'11 results (307.28 KB)
Financial Data

11/05/11 - 2:00

DiaSorin and Labcorp extend strategic business relationship (100.01 KB)
Acquisition / Partnership

06/05/11 - 2:00

Agreement with Precision System Science Co., LTD (171.54 KB)
Acquisition / Partnership

28/04/11 - 2:00

The Ordinary Shareholders' meeting approves the 2010 statutory financial statements and the dividend distribution (175.61 KB)
Financial Data

16/03/11 - 1:00

The BoD approves FY'10 results (368.28 KB)
Financial Data

16/03/11 - 1:00

Dividend information amendment (159.83 KB)
Financial Data

28/02/11 - 1:00

2011 Financial calendar update (179.92 KB)
Financial Data

19/02/11 - 1:00

Notice of change in share capital (5.28 KB)
Financial Data

18/02/11 - 1:00

Buy-back plan (134.06 KB)
Financial Data

17/02/11 - 1:00

Financial instruments to employees (56.37 KB)
Financial Data

16/02/11 - 1:00

Buy-back plan (105.2 KB)
Financial Data

15/02/11 - 1:00

Buy-back plan (91.38 KB)
Financial Data

14/02/11 - 1:00

The BoD approves Q4'10 results (161 KB)
Financial Data

31/01/11 - 1:00

Buy-back plan (105.05 KB)
Financial Data

29/01/11 - 1:00

Buy-back plan (105.2 KB)
Financial Data

28/01/11 - 1:00

Buy-back plan (105.04 KB)
Financial Data

27/01/11 - 1:00

Buy-back plan (105.04 KB)
Financial Data

26/01/11 - 1:00

FDA approves the LIAISON XL (194.2 KB)
Products Immunodiagnostic

25/01/11 - 1:00

Buy-back plan (105.22 KB)
Financial Data

24/01/11 - 1:00

Buy-back plan (104.72 KB)
Financial Data

21/01/11 - 1:00

Buy-back plan (105.05 KB)
Financial Data

20/01/11 - 1:00

Buy-back plan (91.39 KB)
Financial Data

19/01/11 - 1:00

Buy-back plan (105.31 KB)
Financial Data

18/01/11 - 1:00

Buy-back plan (35.47 KB)
Financial Data

17/01/11 - 1:00

Buy-back plan (134.01 KB)
Financial Data

17/01/11 - 1:00

The Sonic Healthcare Group chooses DiaSorin (181.71 KB)
Acquisition / Partnership

16/01/11 - 1:00

2011 Financial calendar (179.49 KB)
Financial Data

22/12/10 - 1:00

2011 Financial calendar (180.28 KB)
Financial Data

20/12/10 - 1:00

Dividend may be distributed in June (445.78 KB)
Financial Data

02/12/10 - 1:00

Comment on position Paper on Vitamin D (53.46 KB)
Products Immunodiagnostic

24/11/10 - 1:00

Change in share capital (46.85 KB)
Financial Data

18/11/10 - 1:00

Financial instruments to employees (48.33 KB)
Financial Data

05/11/10 - 1:00

The BoD approves Q3'10 results (414.16 KB)
Financial Data

02/11/10 - 1:00

Change in share capital (313.61 KB)
Financial Data

08/10/10 - 2:00

2010 Financial calendar update (174.1 KB)
Financial Data

30/09/10 - 2:00

Change in share capital (5.25 KB)
Financial Data

24/09/10 - 2:00

Financial instruments to employees (48.81 KB)
Financial Data

16/09/10 - 2:00

Stock options exercised by key managers (195.67 KB)
Financial Data

02/09/10 - 2:00

Financial instruments to employees (24.27 KB)
Financial Data

06/08/10 - 2:00

The BoD approves H1'10 results (287.11 KB)
Financial Data

07/07/10 - 2:00

Agreement with Meridian Inc. (182.7 KB)
Acquisition / Partnership

06/07/10 - 2:00

2010 Financial calendar update (174.1 KB)
Financial Data

02/07/10 - 2:00

Financial instruments to employees (24.37 KB)
Financial Data

01/06/10 - 2:00

Acquisition of MUREX product line (102.6 KB)
Acquisition / Partnership

14/05/10 - 2:00

The BoD approves Q1'10 results (254.05 KB)
Financial Data

27/04/10 - 2:00

Approval of statutory financial statements (182.99 KB)
Financial Data

20/04/10 - 2:00

2010 Financial calendar update (168.23 KB)
Financial Data

14/04/10 - 2:00

Postponement of the term for lists of members of the Board of Auditors (40.34 KB)
Financial Data

09/04/10 - 2:00

China approves new prenatal screening product line on LIAISON (141.08 KB)
Products Immunodiagnostic

02/04/10 - 2:00

Financial instruments to employees (27.79 KB)
Financial Data

22/03/10 - 1:00

The BoD approves FY 2009 results (306.02 KB)
Financial Data

10/03/10 - 1:00

Acquisition of MUREX product line (45.5 KB)
Acquisition / Partnership

01/03/10 - 1:00

2010 Financial calendar update (192.49 KB)
Financial Data

12/02/10 - 1:00

The BoD approves Q4'09 results (213.8 KB)
Financial Data

18/01/10 - 1:00

2010 Financial calendar (103 KB)
Financial Data

24/12/09 - 1:00

Financial instruments to employees (26.76 KB)
Financial Data

30/10/09 - 1:00

The BoD approves Q3'09 results (212.92 KB)
Financial Data

12/10/09 - 2:00

Strengthening of group's R&D team (99.72 KB)
Other

08/10/09 - 2:00

2009 Financial calendar update (97.3 KB)
Financial Data

05/10/09 - 2:00

Financial instruments to employees (27.08 KB)
Financial Data

06/08/09 - 2:00

The BoD approves H1'09 results (214.79 KB)
Financial Data

08/06/09 - 2:00

2009 Financial calendar update (97.33 KB)
Financial Data

18/05/09 - 2:00

Financial instruments to employees (26.65 KB)
Financial Data

10/04/09 - 2:00

Corporate Governance Report at December 2008. (97.57 KB)
Financial Data

08/04/09 - 2:00

2009 Financial calendar update (103.88 KB)
Financial Data

19/03/09 - 1:00

The BoD approves FY 2008 results (221.59 KB)
Financial Data

20/02/09 - 1:00

Financial instruments to employees (26.39 KB)
Financial Data

13/02/09 - 1:00

The BoD approves Q4'08 results (170.79 KB)
Financial Data

28/01/09 - 1:00

2009 Financial calendar (93.96 KB)
Financial Data

08/01/09 - 1:00

FDA clearance to five LIAISON products (96.84 KB)
Products Immunodiagnostic

23/12/08 - 1:00

Financial instruments to employees (26.19 KB)
Financial Data

21/11/08 - 1:00

Financial instruments to employees (23.66 KB)
Financial Data

13/11/08 - 1:00

The BoD approves Q3'08 results (171.93 KB)
Financial Data

22/09/08 - 2:00

Agreement in Japan with Advanced Life Science Institute (99.16 KB)
Acquisition / Partnership

08/08/08 - 2:00

The BoD approves H1'08 results (194.3 KB)
Financial Data

09/07/08 - 2:00

Acquisition of Biotrin (99.08 KB)
Acquisition / Partnership

16/05/08 - 2:00

Financial instruments to employees (23.28 KB)
Financial Data

15/05/08 - 2:00

Results for Q1'08 (159.78 KB)
Financial Data

24/04/08 - 2:00

2007 statutory financial Statements approved (93.67 KB)
Financial Data

21/04/08 - 2:00

2008 Financial calendar update (93.56 KB)
Financial Data

19/03/08 - 1:00

The BoD approves FY 2007 results (198.25 KB)
Financial Data

14/02/08 - 1:00

The BoD approves Q4'07 results (170.91 KB)
Financial Data

29/01/08 - 1:00

2008 Financial calendar (88.78 KB)
Financial Data

07/01/08 - 1:00

Financial instruments to employees (29.51 KB)
Financial Data